Evelo Biosciences

620 Memorial Drive Suite 500
United States

Show jobs for this employer

About Evelo Biosciences

The gut is a central organ of the immune system which controls immunity and inflammation through its interactions with microbes in the small intestine

We are developing a new class of oral biologic therapies that engage immune cells in the small intestine to transmit effects throughout the body

Modulation of this “gut-body network" has therapeutic potential in many major diseases

For general inquiries contact: info@evelobio.com

For media inquiries contact: media@evelobio.com

For investor inquiries contact: ir@evelobio.com


1 article with Evelo Biosciences

  • Evelo Biosciences, Inc., a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures, a healthcare investment firm.